All‐cause mortality · patients with primary biliary cirrhosis.
It is very uncertain whether ursodeoxycholic acid changes all‐cause mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality or liver transplantation · patients with primary biliary cirrhosis.
It is very uncertain whether ursodeoxycholic acid changes all‐cause mortality or liver transplantation compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether ursodeoxycholic acid changes serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Non‐serious adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether ursodeoxycholic acid changes non‐serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Pruritus · patients with primary biliary cirrhosis.
Ursodeoxycholic acid showed no clear difference in pruritus compared with placebo or no intervention (low certainty).
1 finding from 1 review
Bilirubin (µmol/L) · patients with primary biliary cirrhosis.
1 finding from 1 review
Liver biopsy findings (worsening of histological stage) · patients with primary biliary cirrhosis.
It is very uncertain whether ursodeoxycholic acid changes liver biopsy findings (worsening of histological stage) compared with placebo or no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes mortality compared with placebo (very low certainty).
1 finding from 1 review
Cholecystectomy · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with adverse events · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes proportion of people with adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number of adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary sclerosing cholangitis
1 finding from 1 review
Liver transplantation · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes liver transplantation compared with placebo (very low certainty).
1 finding from 1 review
Malignancy · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cholangiocarcinoma · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes cholangiocarcinoma compared with placebo (very low certainty).
1 finding from 1 review
Colorectal cancer · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pruritus · pregnant women with intrahepatic cholestasis
1 finding from 1 review
Stillbirth · pregnant women with intrahepatic cholestasis
It is very uncertain whether ursodeoxycholic acid (UDCA) changes stillbirth compared with placebo (very low certainty).
1 finding from 1 review
Fetal distress/asphyxial events · pregnant women with intrahepatic cholestasis
It is very uncertain whether ursodeoxycholic acid (UDCA) changes fetal distress/asphyxial events compared with placebo (very low certainty).
1 finding from 1 review